← Eichor
Condition: Recurrent Liver Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Liver Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT05444478Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07014150Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme
Phase 2 · 41 location(s) · UNICANCER · NCT06475352Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06454578Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
NA · 1 location(s) · Sun Yat-sen University · NCT06609876Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-R
Phase N/A · 1 location(s) · Tian'an Jiang · NCT06577272Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
Phase N/A · 1 location(s) · Tongji Hospital · NCT06653062Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
NA · 1 location(s) · Asan Medical Center · NCT06537193Recurrent Liver Cancer: Reconceptualization and Reevaluation
Phase N/A · 1 location(s) · Nanjing Medical University · NCT06430983HOPE Against Cancer Recurrence in HCC
Phase 4 · 37 location(s) · Philipp Dutkowski · NCT06717919Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcin
Phase 2 · 1 location(s) · Northern Jiangsu People's Hospital · NCT07337421To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With H
Phase 1 · 2 location(s) · Shenzhen Xinhe Biomedical · NCT07594964Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
NA · 1 location(s) · Beijing Hospital · NCT05738980Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepato
Phase N/A · 1 location(s) · Zhujiang Hospital · NCT06861114A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Phase 3 · 1 location(s) · Akeso · NCT05489289Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06581315Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepato
Phase N/A · 1 location(s) · University Hospital, Ghent · NCT05866783Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT04803318Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies
Phase 1 · 1 location(s) · Hua Li · NCT05803928The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT06609850Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT04615143Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
Phase 1/Phase 2 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT05323201Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer
NA · 1 location(s) · Fudan University · NCT06934018Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
NA · 1 location(s) · University Hospital, Rouen · NCT05375370Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Phase 1/Phase 2 · 1 location(s) · Tongji Hospital · NCT07282184cfDNA Methylation for Liver Cancer Recurrence Detection
Phase N/A · 1 location(s) · Wuhan Ammunition Life-tech Co., Ltd · NCT07466602Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
EARLY_Phase 1 · 1 location(s) · Chang Gung Memorial Hospital · NCT06327269Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06532799
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.